UNMC Licenses Investigational Therapy (Low-Dose Interleukin-2) to Houston-based Biotech Targeting Parkinson’s Disease

Earlier this year, the University of Nebraska Medical Center (UNMC) reported on some progress in investigating an innovative approach to treat Parkinson&rsquo;s disease. In fact, pioneered at UNMC, the experimental regimen could reach patients within the next year as part of a clinical trial. The genesis for this experimental therapeutic approach involved both Howard Gendelman, M.D., and Lee Mosley, Ph.D.&mdash;both of whom first identified ld-IL-2 monotherapy &mdash; short for low-dose interleukin-2 &mdash; as a potential treatment for Parkinson&rsquo;s disease. In parallel, an emerging pharmaceutical company called Coya Therapeutics just happened to be working on pioneering work with Id-IL-2 in an effort targeting multiple neurodegenerative conditions. The latter had generated promising clinical data targeting both ALS and Alzheimer&rsquo;s disease. Then there came the UNMC data, which spurred the company to ink a licensing partnership with the academic medical center. The target: Parkinson&rsquo;s disease. 
Background